Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer

Sponsor
Fudan University
Study ID
NCT06636591
Status
Recruiting
Apply to this trial

Conditions

  • Breast Cancer Female
  • HER2-negative Breast Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

In this study, breast cancer (BC) patients eligible for inclusion will be divided into two groups according to molecular typing and subtyping, which combined immunotherapy and multimodal thermal therapy with conventional neoadjuvant chemotherapy, to explore methods of immune induction for BC, enhance the efficacy of immunotherapy, and accumulate data for subsequent stages of clinical study.

Key Dates

Start date
Nov 18, 2024
Status verified
Nov 2024
Primary completion
Feb 7, 2025
Completion
Oct 7, 2026

Study Design

Enrollment
14 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Triple-negative Breast Cancer with Non-immunomodulatory Subtype
  • Experimental: Hormone Receptor-positive (HR+) and HER2-negative (HER2-)

Primary Outcome Measure

Assessment of immune activating response [ Time Frame: up to 28 weeks ]

Central Contacts

Related Studies